logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $8.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed positioned 'exceptionally well' to complete...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has launched a financial restructuring plan, where the company’s lead investor Yorkville Advisors Global will convert a minimum of $3.8 million into common stock and preferred stock and may convert an additional $500,000. Corin says...

12 minutes ago

2 min read